300760:SZSEShenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A Analysis
Data as of 2026-06-06 - not real-time
CN¥144.39
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Shenzhen Mindray is trading below its 20‑day, 50‑day and 200‑day simple moving averages, with the 14‑day RSI around the low‑30s, signalling short‑term oversold conditions and a bearish technical backdrop.
Fundamentally, the stock trades at a forward PE well below the industry average, offers a dividend yield above 4% with a payout ratio under 75%, and maintains a strong cash position versus modest debt, suggesting solid financial health. The DCF‑derived fair value is considerably lower than the current price, creating a tension between valuation models, while the analyst consensus leans strongly bullish, highlighting growth potential from its diversified medical‑device portfolio.
Fundamentally, the stock trades at a forward PE well below the industry average, offers a dividend yield above 4% with a payout ratio under 75%, and maintains a strong cash position versus modest debt, suggesting solid financial health. The DCF‑derived fair value is considerably lower than the current price, creating a tension between valuation models, while the analyst consensus leans strongly bullish, highlighting growth potential from its diversified medical‑device portfolio.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below key moving averages and bearish MACD
- Support level near current price offering downside protection
- Attractive dividend yield providing income while awaiting technical bounce
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward earnings growth outpacing current valuation
- Undervalued relative to industry PE and strong cash generation
- Continued dividend support enhancing total return
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust product portfolio in a growing healthcare sector
- Low beta and stable liquidity reducing market volatility exposure
- Strategic positioning in China’s expanding medical‑device market
Key Metrics & Analysis
Financial Health
Revenue Growth1.40%
Profit Margin23.47%
P/E Ratio22.3
ROE18.52%
ROA9.80%
Debt/Equity0.77
P/B Ratio4.4
Op. Cash FlowCN¥10.0B
Free Cash FlowCN¥6.0B
Industry P/E27.9
Technical Analysis
TrendBearish
RSI31.5
SupportCN¥141.88
ResistanceCN¥170.90
MA 20CN¥154.75
MA 50CN¥159.69
MA 200CN¥197.43
MACDBearish
VolumeStable
Fear & Greed Index83.02
Valuation
Fair ValueCN¥84.00
Target PriceCN¥237.20
Upside/Downside64.28%
GradeFair
TypeBlend
Dividend Yield4.29%
Risk Assessment
Beta0.11
Volatility28.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.